Dr. Excoffon describes her academic experience that led her to the field and Spirovant Sciences, discusses interesting data from last month’s North American Cystic Fibrosis Conference, and then highlights Spirovant’s program and why using a small molecule modulator like doxorubicin might be the key to success.